title: Peptides in the treatment of AIDS.
abstract: Fusion of HIV-1 and target cells is mediated by the envelope protein gp41 that undergoes a series of conformational changes during the process of infection. Knowledge of the structural biology of gp41 allows the design of potent peptide inhibitors that prevent the virus from entering lymphocytes and macrophages. The design of such inhibitors is the subject of this review.
authors.affiliation: Department of Chemistry, College of Staten Island of the City University of New York, Staten Island, New York 10314, USA. naider@mail.csi.cuny.edu
authors.forename: Fred
authors.initials: F
authors.lastname: Naider
authors.forename: Jacob
authors.initials: J
authors.lastname: Anglister
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000595:Amino Acid Sequence; D000818:Animals; D015195:Drug Design; D023581:HIV Fusion Inhibitors / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism
chemical_list: D023581:HIV Fusion Inhibitors; D010455:Peptides; D014759:Viral Envelope Proteins